TW239869B - - Google Patents

Download PDF

Info

Publication number
TW239869B
TW239869B TW081105670A TW81105670A TW239869B TW 239869 B TW239869 B TW 239869B TW 081105670 A TW081105670 A TW 081105670A TW 81105670 A TW81105670 A TW 81105670A TW 239869 B TW239869 B TW 239869B
Authority
TW
Taiwan
Prior art keywords
compound
annexin
conjugate
item
patent application
Prior art date
Application number
TW081105670A
Other languages
English (en)
Chinese (zh)
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of TW239869B publication Critical patent/TW239869B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW081105670A 1991-05-09 1992-07-17 TW239869B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69736491A 1991-05-09 1991-05-09

Publications (1)

Publication Number Publication Date
TW239869B true TW239869B (enExample) 1995-02-01

Family

ID=24800848

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081105670A TW239869B (enExample) 1991-05-09 1992-07-17

Country Status (5)

Country Link
EP (1) EP0538459A4 (enExample)
JP (1) JPH05508664A (enExample)
CA (1) CA2086437A1 (enExample)
TW (1) TW239869B (enExample)
WO (1) WO1992019279A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178476A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
CA2180555C (en) * 1994-01-24 2004-12-14 Sudhakar Kasina Radiolabeled annexins
EP1364964A1 (en) * 1994-06-16 2003-11-26 Neorx Corporation Radiolabeled annexingalactose conjugates
JPH10504534A (ja) * 1994-06-16 1998-05-06 ネオルクス コーポレイション 放射性標識アネキシン−ガラクトース結合体
CA2206274C (en) * 1994-12-07 2009-06-30 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
EP1486509A3 (en) * 1994-12-07 2005-03-23 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
HUP0001261A3 (en) 1997-04-30 2001-11-28 Univ Washington Seattle Method of imaging cell death in vivo
US6511829B1 (en) * 1997-10-09 2003-01-28 The Regents Of The University Of California GFP-annexin fusion proteins
FR2784106B1 (fr) 1998-10-02 2002-04-19 Commissariat Energie Atomique Structure chimique ayant une affinite pour un phospholipide, et compose de marquage, trousse de diagnostic, et medicament comprenant cette structure
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US6962903B2 (en) * 2001-02-21 2005-11-08 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
CA2443314C (en) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
EP1372740A2 (en) 2001-04-03 2004-01-02 Theseus Imaging Corporation Methods for using annexin for detecting cell death in vivo and treating associated conditions
FR2841558B1 (fr) * 2002-07-01 2004-08-13 Commissariat Energie Atomique Peptides marques ayant une affinite pour un phospholipide et utilisations
FR2841557B1 (fr) * 2002-07-01 2005-12-09 Commissariat Energie Atomique Peptides ayant une affinite pour un phospholipide et utilisations
FR2856069A1 (fr) * 2003-06-10 2004-12-17 Bionexis Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation
US20190248920A1 (en) 2016-09-23 2019-08-15 Csl Limited Coagulation factor binding proteins and uses thereof
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
WO1992005749A1 (en) * 1990-10-04 1992-04-16 New England Deaconess Hospital Corporation Soluble thrombogenesis inhibitor conjugates

Also Published As

Publication number Publication date
CA2086437A1 (en) 1992-11-10
WO1992019279A1 (en) 1992-11-12
EP0538459A1 (en) 1993-04-28
JPH05508664A (ja) 1993-12-02
EP0538459A4 (en) 1993-06-16

Similar Documents

Publication Publication Date Title
TW239869B (enExample)
US5632986A (en) Phospholipid-targeted thrombolytic agents
TW538048B (en) A soluble derivative of a soluble polypeptide and its use
RU2466141C2 (ru) МОДИФИЦИРОВАННЫЙ КОАГУЛИРУЮЩИЙ ФАКТОР VIIa С ПРОДЛЕННЫМ ВРЕМЕНЕМ ПОЛУЖИЗНИ
TW587081B (en) Vitamin K-dependent polypeptide with enhanced membrane binding affinity, protein C or activated protein C polypeptide, and pharmaceutical composition thereof
US5011686A (en) Thrombus specific conjugates
JPH05508766A (ja) フィブリン結合ドメインポリペプチド及びその使用，並びにその製造方法
KR101492422B1 (ko) 치료용 폴리펩타이드의 생체내 회수율을 증가시키는 방법
MX2010010759A (es) Mutantes de estreptocinasa y sus formas covalentemente modificadas.
JP2007528847A (ja) 通常の細胞保護活性を有するが抗凝固活性が低下した活性化プロテインｃ変異体
EA005944B1 (ru) Фибринолитически активный полипептид
US5474766A (en) Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
JPH05506646A (ja) ヒト・フォンビルブラント因子のクローニング及び製造、並びにその使用方法
JPH10505502A (ja) 修飾されたコラーゲン誘導血小板凝集阻害剤パリジピンの製法
JPH04505554A (ja) 可溶性トロンボモジュリン類似体
Jing et al. An αIIbβ3-and phosphatidylserine (PS)-binding recombinant fusion protein promotes PS-dependent anticoagulation and integrin-dependent antithrombosis
Iwao et al. Altered chain-length and glycosylation modify the pharmacokinetics of human serum albumin
WO2002014369A9 (en) Human kininogen d5 domain polypeptides and their use
US20030082740A1 (en) Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent
JP3095771B2 (ja) ヒトフィブロネクチンポリペプチド類似体のクローニング及び製造並びにこのようなポリペプチド類似体の使用法
MIRZA jllafiter of $ l| ilofl (oplip
WO2011063921A1 (en) Acceleration of wound healing by a tissue inhibitor of metalloproteinases (timp) linked to glycosylphosphatidylinositol (gpi)-anchors
Speziale The thiols in platelet thrombospondin: evidence of intramolecular thiol-disulfide exchange
AU2013202563A1 (en) Method of increasing the in vivo recovery of therapeutic polypeptides
HK1129421B (en) Modified coagulation factor vila with extended half-life